Latest News and Press Releases

To NASDAQ OMX Copenhagen A/S Announcement no. 02-14 / Copenhagen, February 6, 2014 Topotarget A/S announces that the FDA has granted acceptance to file and Priority Review for the BeleodaqTM NDA...

To NASDAQ OMX Copenhagen A/S Announcement no. 01-14 / Copenhagen, January 30, 2014 Topotarget announces that the board of directors has reviewed and approved the company’s interim report for the...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 01-14 / København, 30. januar 2014 Topotarget meddeler, at bestyrelsen i dag har behandlet og godkendt selskabets delårsrapport for perioden 1. januar...

Til NASDAQ OMX Copenhagen A/S Investor Nyhed nr. 01-14 / København, 23. januar 2014 Topotarget afholder telekonference vedr. selskabets delårsrapport for perioden 1. januar – 31. december 2013...

To NASDAQ OMX Copenhagen A/S Investor News no. 01-14 / Copenhagen, January 23, 2014 Topotarget will host a teleconference regarding the company’s interim report for the period January 1 –...

To NASDAQ OMX Copenhagen A/S Announcement no. 28-13 / Copenhagen, December 10, 2013 Topotarget announces the submission of a New Drug Application (NDA) for belinostat for the treatment of...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 28-13 / København, 10. december 2013 Topotarget meddeler hermed, at der er indsendt en registreringsansøgning (NDA) til de amerikanske...

To NASDAQ OMX Copenhagen A/S Announcement no. 27-13 / Copenhagen, November 21, 2013 The European patent covering Composition of Matter for belinostat has been granted. The patent will protect...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 27-13 / København, 21. november 2013 Der er tildelt europæisk patent, som dækker stofkrav for belinostat. Patentet vil beskytte belinostat mod...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 26-13 / København, 20. november 2013 Topotarget offentliggør de endelige resultater fra det første stadie af fase II-delen af det kliniske fase...